Vemurafenib for melanoma metastases to the brain

New England Journal of Medicine

Volumn 365, Issue 25, 2011, Pages 2439-2441

  Rochet, Nicole M ^a   Kottschade, Lisa A ^a   Markovic, Svetomir N ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; INTERLEUKIN 2; IPILIMUMAB; VEMURAFENIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; RAF PROTEIN; SULFONAMIDE;

ADOLESCENT; BRAIN METASTASIS; CASE REPORT; CLINICAL FEATURE; CONFUSION; DISEASE COURSE; DIZZINESS; FEMALE; HEADACHE; HUMAN; LETTER; LOW DRUG DOSE; MELANOMA; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEIZURE; SOMNOLENCE; STEREOTAXIC SURGERY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; BRAIN TUMOR; DRUG ANTAGONISM; METASTASIS; REMISSION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; HUMANS; INDOLES; MELANOMA; RAF KINASES; REMISSION INDUCTION; SULFONAMIDES;

EID: 84855179546     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1111672     Document Type: Letter

References (3)

1. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596-9.
2. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54. (Pubitemid 34716871)